High Tide Inc. — Cyborg Score 7/10

Strong
Cannabis Retail & Distribution

Strategic Profile

High Tide operates across data analytics, advertising, product sourcing, medical cannabis distribution, and accessories retail through a network of physical stores, e-commerce platforms, and wholesale distribution. The company is a retail-forward enterprise built to deliver value across the cannabis ecosystem.

Cyborg Score Rationale

High Tide reported fiscal 2025 revenue of $593.99 million, representing 13.72% growth year-over-year. The company added 34 Canna Cabana stores in 2025 and closed a 51% acquisition of Remexian Pharma to enter the German medical cannabis market. Management expects to remain free cash flow positive for the 2026 fiscal year.

Top Insights

  • As of February 2026, High Tide operates 219 Canna Cabana locations in Canada with 95 in Ontario, representing continued disciplined expansion.
  • The White House Executive Order on cannabis rescheduling and announced Medicare CBD pilot create opportunities for High Tide's NuLeaf Naturals and FAB CBD brands.
  • Q4 gross profit reached $42.5M with 26% margin and cash position of $47.9M as of October 31, 2025.
  • High Tide is evaluating Canna Cabana licensing opportunities with major U.S. operators and exploring international expansion through Remexian partnerships.

Named Competitors

  • Multi-brand Retail Network — Independent cannabis retailers and regional chains in Canada and U.S.
  • E-commerce Accessories — Online consumption accessories retailers (brands owned by High Tide)
  • Retail Pharmacy — Potential competitors for CBD/pharmaceutical distribution post-regulation

Recent Developments

  • (February 2026) Opened 219th Canna Cabana store in Scarborough, Ontario on February 9, 2026.
  • (January 2026) Reported fiscal 2025 year-end results with record revenue and adjusted EBITDA.
  • (December 2025) Welcomed White House Executive Order advancing cannabis rescheduling and Medicare CBD pilot program announcement.
  • (Calendar 2025) Added 34 Canna Cabana stores and closed 51% acquisition of Remexian Pharma for German medical cannabis market entry.

Open the full interactive High Tide Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →